Stille AB (STIL) Fair Value & Analysis
Healthcare · SE · Market cap 2.3B SEK
Fair value as of: Jun 24, 2026
Analysis
Stille AB (STIL) currently trades at kr 249.00, while our model-based Fair Value estimate is kr 136.38 — implying the stock looks roughly 45.2% overvalued today. We read business quality at 95/100 (high quality), in the Healthcare sector. Bear case: priced above our estimate, the market already discounts strong expectations. Bull case: above-average quality can justify a premium — the entry price still matters most (evidence: high).
About the company
Stille AB develops, manufactures, and distributes medtech products in Sweden, Germany, the United Kingdom, Switzerland, North America, the United States, and internationally. It operates through the Surgical Instruments and Surgical Tables segments. The Surgical Instruments segment offers surgical scissors, including SuperCut, eye, blepharoplasty, operating, vascular, tenotomy, and face-lift scissors; colon, gall duct, multi-purpose, tangential occlusion, peripheral vascular, and anastomosis clamps; skin and nerve hooks, retractors, rib spreaders, self-retaining and trachea retractors, and nasal specula; and dressing, diathermy, knot-holding, tissue, iris, dura, and vascular forceps under the STILLE, Fehling, S&T, and Surgical Holdings brands. Its Surgical Tables segment provides C-arm tables, which are surgical tables used in advanced imaging, cardiac electrophysiology, cardiovascular and vascular, gastrointestinal and abdominal, interventional radiology, neuro/spine, pain manageme…
Open the full interactive analysis →
Similar stocks
Frequently asked questions
Is Stille AB (STIL) undervalued?
What is the fair value of STIL?
What is the quality score of STIL?
How we calculate Fair Value
Each company is valued through a stack of independent intrinsic-value models (DCF variants, residual-income, multiples and more), blended into one family-balanced consensus and weighted by how much trustworthy data backs it. A separate quality layer scores the fundamentals. Every input is real reported data — nothing guessed.
Educational research only · not financial advice · no buy/sell recommendation. Model-based estimates are not certainties; their reliability depends on data quality and assumptions.